Login / Signup

The intraoperative use of recombinant activated factor VII in arterial switch operations.

Jessica ZinkZachary A SpigelChristopher IbarraErin A GottliebIki AdachiCarlos M MeryMichiaki ImamuraJeffrey S HeinleEmmett Dean McKenzieCharles D FraserZiyad M Binsalamah
Published in: Cardiology in the young (2020)
In spite of a higher post-bypass packed red blood cell transfusion requirement, patients receiving recombinant factor VIIa had a similar incidence of bleeding post-operatively. With no difference in thrombotic complications, and with improved post-operative laboratory haemostasis, a prospective randomised study is warranted to evaluate recombinant factor VIIa.
Keyphrases
  • red blood cell
  • risk factors
  • clinical trial
  • cell free
  • open label
  • cardiac surgery
  • atrial fibrillation
  • patients undergoing
  • randomized controlled trial
  • sickle cell disease